Asian Phase I Study Of PF-03446962

A Phase I Pharmacokinetic And Pharmacodynamic Study Of Pf-03446962 In Asian Patient With Advanced Solid Tumors

This is an Asian Phase 1, multi center, open label, single arm study of PF 03446962 with dose escalation and designed to define the Maximum Tolerated Dose [MTD] and the Recommended Phase 2 Dose [RP2D].

Inclusion Criteria:

• Confirmed diagnosis of stomach cancer
• advanced/metastasis solid tumor refractory or intolerant to established therapy
• adequate blood chemistry, blood counts and kidney/liver function
• willing to participate to study requirements and sign an informed consent document

Exclusion Criteria:

• Chemotherapy, radiotherapy, or any investigational cancer therapy within 4 weeks of first dose of study medication
• excessive toxicities related to prior therapies
• pregnant or breastfeeding patients